JP2013517487A - がん幹細胞マーカーおよびその使用 - Google Patents

がん幹細胞マーカーおよびその使用 Download PDF

Info

Publication number
JP2013517487A
JP2013517487A JP2012549291A JP2012549291A JP2013517487A JP 2013517487 A JP2013517487 A JP 2013517487A JP 2012549291 A JP2012549291 A JP 2012549291A JP 2012549291 A JP2012549291 A JP 2012549291A JP 2013517487 A JP2013517487 A JP 2013517487A
Authority
JP
Japan
Prior art keywords
cancer
tumor
cells
cancer stem
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2012549291A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013517487A5 (enExample
Inventor
シュテファン ゴレツ，
ウヴェ カルステン，
Original Assignee
グリコトープ ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グリコトープ ゲーエムベーハー filed Critical グリコトープ ゲーエムベーハー
Publication of JP2013517487A publication Critical patent/JP2013517487A/ja
Publication of JP2013517487A5 publication Critical patent/JP2013517487A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5756—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving tumour-associated glycolinkage [TAG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2012549291A 2010-01-20 2011-01-20 がん幹細胞マーカーおよびその使用 Ceased JP2013517487A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US29673810P 2010-01-20 2010-01-20
EP10000527A EP2347769A1 (en) 2010-01-20 2010-01-20 Cancer stem cell markers and uses thereof
EP10000527.1 2010-01-20
US61/296,738 2010-01-20
PCT/EP2011/000217 WO2011089004A1 (en) 2010-01-20 2011-01-20 Cancer stem cell markers and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015253064A Division JP2016047848A (ja) 2010-01-20 2015-12-25 がん幹細胞マーカーおよびその使用

Publications (2)

Publication Number Publication Date
JP2013517487A true JP2013517487A (ja) 2013-05-16
JP2013517487A5 JP2013517487A5 (enExample) 2014-02-06

Family

ID=42173400

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012549291A Ceased JP2013517487A (ja) 2010-01-20 2011-01-20 がん幹細胞マーカーおよびその使用
JP2015253064A Withdrawn JP2016047848A (ja) 2010-01-20 2015-12-25 がん幹細胞マーカーおよびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015253064A Withdrawn JP2016047848A (ja) 2010-01-20 2015-12-25 がん幹細胞マーカーおよびその使用

Country Status (8)

Country Link
US (1) US20120294859A1 (enExample)
EP (2) EP2347769A1 (enExample)
JP (2) JP2013517487A (enExample)
CN (1) CN102753199A (enExample)
AU (1) AU2011208874B2 (enExample)
BR (1) BR112012018132A2 (enExample)
CA (1) CA2786212A1 (enExample)
WO (1) WO2011089004A1 (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018510844A (ja) * 2015-01-24 2018-04-19 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ がんマーカーおよびその使用方法
WO2018092885A1 (ja) * 2016-11-18 2018-05-24 アステラス製薬株式会社 新規な抗ヒトＭＵＣ１抗体Ｆａｂフラグメント
US11667724B2 (en) 2017-07-07 2023-06-06 Astellas Pharma Inc. Anti-human CEACAM5 antibody Fab fragment
JP2024504406A (ja) * 2021-01-25 2024-01-31 ユニオジェン・オサケユフティオ 膀胱がんのバイオマーカーとしてのＦＵＣα（１－２）Ｇａｌ糖鎖構造の使用
US12065503B2 (en) 2018-10-10 2024-08-20 Astellas Pharma Inc. Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex
US12202908B2 (en) 2018-05-17 2025-01-21 Astellas Pharma Inc. Complex having anti-human MUC1 antibody Fab fragment, peptide linker and/or ligand

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
ES2442024T3 (es) 2008-07-15 2014-02-07 Academia Sinica Matrices de glucano sobre portaobjetos de vidrio revestidos con aluminio de tipo PTFE y métodos relacionados
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10338069B2 (en) 2010-04-12 2019-07-02 Academia Sinica Glycan arrays for high throughput screening of viruses
EP2689787A1 (en) 2010-09-03 2014-01-29 Stem Centrx, Inc. Identification and enrichment of cell subpopulations
US9778264B2 (en) 2010-09-03 2017-10-03 Abbvie Stemcentrx Llc Identification and enrichment of cell subpopulations
WO2012039430A1 (ja) * 2010-09-21 2012-03-29 株式会社Ｇｐバイオサイエンス がん幹細胞の単離方法
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
WO2014031498A1 (en) 2012-08-18 2014-02-27 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
US9341619B2 (en) 2013-03-14 2016-05-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hyposialylation disorders
EP3013365B1 (en) 2013-06-26 2019-06-05 Academia Sinica Rm2 antigens and use thereof
EP3013347B1 (en) 2013-06-27 2019-12-11 Academia Sinica Glycan conjugates and use thereof
JP6486368B2 (ja) 2013-09-06 2019-03-20 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 改変されたグリコシル基を含む糖脂質を用いたヒトｉＮＫＴ細胞の活性化
BR112015032713B1 (pt) 2013-09-17 2023-03-21 Obi Pharma, Inc Composto, composição farmacêutica, uso de uma quantidade terapeuticamente efetiva da composição farmacêutica, e uso do composto
AU2015206370A1 (en) 2014-01-16 2016-07-07 Academia Sinica Compositions and methods for treatment and detection of cancers
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
CN106415244B (zh) 2014-03-27 2020-04-24 中央研究院 反应性标记化合物及其用途
US10023651B2 (en) 2014-04-18 2018-07-17 The Research Foundation For The State University Of New York Humanized anti-TF-antigen antibodies
RU2699717C2 (ru) * 2014-04-18 2019-09-09 Дзе Ресёч Фаундэйшен Фор Дзе Штат Юниверсити Ов Нью-Йорк Гуманизированные антитела к антигену Томсена-Фриденрайха
CN103969437B (zh) * 2014-04-22 2017-03-22 广州恒泰生物科技有限公司 用于卵巢癌早中期快速诊断试剂盒的制备方法
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
CN106661099A (zh) 2014-05-27 2017-05-10 中央研究院 抗her2醣抗体及其用途
JP7093612B2 (ja) 2014-05-27 2022-06-30 アカデミア シニカ Ｂａｃｔｅｒｏｉｄｅｓ由来のフコシダーゼおよびそれを使用する方法
CA2950415A1 (en) 2014-05-27 2015-12-03 Academia Sinica Anti-cd20 glycoantibodies and uses thereof
WO2015184001A1 (en) 2014-05-28 2015-12-03 Academia Sinica Anti-tnf-alpha glycoantibodies and uses thereof
TWI745275B (zh) 2014-09-08 2021-11-11 中央研究院 使用醣脂激活人類ｉＮＫＴ細胞
FI3218005T3 (fi) 2014-11-12 2023-03-31 Seagen Inc Glykaanin kanssa vuorovaikutteisia yhdisteitä ja käyttömenetelmiä
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
JP6779887B2 (ja) 2015-01-24 2020-11-04 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 新規なグリカンコンジュゲートおよびその使用方法
WO2016137963A1 (en) 2015-02-25 2016-09-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Sialylation-increasing therapies for diseases associated with oxidative stress
US10935544B2 (en) 2015-09-04 2021-03-02 Obi Pharma, Inc. Glycan arrays and method of use
CA3002097A1 (en) 2015-11-12 2017-05-18 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
WO2017100796A1 (en) * 2015-12-11 2017-06-15 SINACA, Academia Modulation of globoseries glycosphingolipid synthesis and cancer biomarkers
EP3426693A4 (en) 2016-03-08 2019-11-13 Academia Sinica PROCESS FOR MODULAR SYNTHESIS OF N-GLYCANES AND ARRANGEMENTS THEREOF
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
BR112018070097A2 (pt) 2016-03-29 2019-02-12 Obi Pharma, Inc. anticorpo, hibridoma, composição farmacêutica, método para tratar câncer em um indivíduo, método para inibir a proliferação de células cancerígenas, método para diagnosticar o câncer em um indivíduo, método para tratar um paciente humano, método para fazer imagens de um indivíduo, conjugado de fármaco-anticorpo (adc), método para tratar câncer, anticorpo biespecífico e método para preparar uma população de anticorpos homogêneos
KR20230110820A (ko) 2016-04-22 2023-07-25 오비아이 파머 인코퍼레이티드 글로보 계열 항원을 통한 면역 활성화 또는 면역 조정에의한 암 면역요법
CN110072545A (zh) 2016-07-27 2019-07-30 台湾浩鼎生技股份有限公司 免疫原性/治疗性聚糖组合物及其用途
US11643456B2 (en) 2016-07-29 2023-05-09 Obi Pharma, Inc. Human antibodies, pharmaceutical compositions and methods
CA3034057A1 (en) 2016-08-22 2018-03-01 CHO Pharma Inc. Antibodies, binding fragments, and methods of use
WO2018094143A1 (en) 2016-11-17 2018-05-24 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
TWI822055B (zh) * 2016-11-21 2023-11-11 台灣浩鼎生技股份有限公司 共軛生物分子、醫藥組成物及方法
WO2018160909A1 (en) 2017-03-03 2018-09-07 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
WO2018178047A1 (en) * 2017-03-29 2018-10-04 Glycotope Gmbh Multispecific antibody constructs binding to muc1 and cd3
TWI877770B (zh) 2018-02-27 2025-03-21 美商英塞特公司 作為a2a / a2b抑制劑之咪唑并嘧啶及三唑并嘧啶
PT110722B (pt) * 2018-05-03 2021-08-17 Instituto De Patologia E Imunologia Molecular Da Univ Do Porto Ipatimup Uso de anticorpos para o antigénio thomsen-friedenreich num método e estojo para avaliação de instabilidade de microsatelites
EP3810610A1 (en) 2018-05-18 2021-04-28 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
SG11202010496WA (en) 2018-05-18 2020-12-30 Daiichi Sankyo Co Ltd Anti-muc1 antibody-drug conjugate
TW202504930A (zh) 2018-06-27 2025-02-01 台灣浩鼎生技股份有限公司 用於糖蛋白工程的糖苷合成酶變體及其使用方法
WO2020010197A1 (en) 2018-07-05 2020-01-09 Incyte Corporation Fused pyrazine derivatives as a2a / a2b inhibitors
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
CN110161241A (zh) * 2019-04-30 2019-08-23 丁晓昆 一种快速检测生物组织切片cosmc基因突变试剂盒
PE20221409A1 (es) 2020-01-03 2022-09-20 Incyte Corp Anticuerpos anti-cd73 y usos de estos
TW202135823A (zh) 2020-01-03 2021-10-01 美商英塞特公司 Ｃｄ７３抑制劑及ａ２ａ／ａ２ｂ腺苷受體抑制劑組合療法
CN111363008B (zh) * 2020-03-18 2021-11-16 北京鼎成肽源生物技术有限公司 一种输卵管癌靶标抗原组合、输卵管癌靶标抗原组合刺激培养的ctl细胞及其应用
AU2021298824A1 (en) * 2020-06-30 2023-01-19 Pentixapharm Ag Humanized antibodies against lewis Y
TW202241441A (zh) 2020-12-29 2022-11-01 美商英塞特公司 包含ａ２ａ／ａ２ｂ抑制劑、ｐｄ－１／ｐｄ－ｌ１抑制劑及抗ｃｄ７３抗體之組合療法
US20240382590A1 (en) * 2021-07-16 2024-11-21 Université de Montréal Novel tumor-specific antigens for cancer stem cells and uses thereof
CN113804531B (zh) * 2021-09-10 2024-02-06 北京大学 一种细胞高活性染色方法
CN115960169A (zh) * 2021-10-09 2023-04-14 清华大学深圳国际研究生院 特异性靶向非小细胞肺癌肿瘤干细胞的多肽及其应用
CN115197915B (zh) * 2022-08-01 2025-08-26 首都医科大学附属北京胸科医院 恶性表型大细胞肺癌细胞株及其应用
CN116718774A (zh) * 2023-07-07 2023-09-08 杭州准星医学科技有限公司 一种用于肿瘤体外诊断的试剂盒及其使用方法
CN121319187B (zh) * 2025-12-08 2026-03-17 宁波大学附属第一医院 一种与cd176蛋白结合的羊驼源纳米抗体及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060251668A1 (en) * 2002-11-29 2006-11-09 Steffen Goletz Tumor-specific recognition molecules
US20090041836A1 (en) * 2006-01-03 2009-02-12 University Of Georgia Research Foundation, Inc. Glycolipopeptide and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020145A (en) * 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
SI1654353T1 (sl) 2003-08-18 2013-09-30 Glycotope Gmbh Tumorski celični liniji NM-F9 (DSM ACC2606) in NM-D4 (DSM ACC2605), njihove uporabe
JP4904266B2 (ja) * 2004-07-26 2012-03-28 ザ リサーチ ファウンデイション オブ ステイト ユニバーシティー オブ ニューヨーク 抗−ｔｆ−抗原抗体の治療的使用
WO2007140011A2 (en) * 2006-05-26 2007-12-06 The Government Of The United States Of America Erythroid progenitor cells and methods for producing parvovirus b19 therein

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060251668A1 (en) * 2002-11-29 2006-11-09 Steffen Goletz Tumor-specific recognition molecules
US20090041836A1 (en) * 2006-01-03 2009-02-12 University Of Georgia Research Foundation, Inc. Glycolipopeptide and uses thereof

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
JPN5013003116; ＩＭＡＩ　ＪＵＮ: 'ＩＭＭＵＮＯＨＩＳＴＯＣＨＥＭＩＣＡＬ　ＥＸＰＲＥＳＳＩＯＮ　ＯＦ　Ｔ，ＴＮ　ＡＮＤ　ＳＩＡＬＹＬ-ＴＮ　ＡＮＴＩＧＥＮＳ　ＡＮＤ　ＣＬＩＮＩＣＡＬ　ＯＵＴＣＯＭＥ　以下備考' ＡＮＴＩＣＡＮＣＥＲ　ＲＥＳＥＡＲＣＨ Ｖ２１　Ｎ２Ｂ, 200103, Ｐ１３２７-１３３４ *
JPN5013003117; ＲＡＧＵＰＡＴＨＩ　Ｇ: 'ＣＡＲＢＯＨＹＤＲＡＴＥ　ＡＮＴＩＧＥＮＳ　ＡＳ　ＴＡＲＧＥＴＳ　ＦＯＲ　ＡＣＴＩＶＥ　ＳＰＥＣＩＦＩＣ　ＩＭＭＵＮＯＴＨＥＲＡＰＹ' ＣＡＮＣＥＲ　ＩＭＭＵＮＯＬＯＧＹ　ＡＮＤ　ＩＭＭＵＮＯＴＨＥＲＡＰＹ Ｖ４３　Ｎ３, 19961101, Ｐ１５２-１５７, ＳＰＲＩＮＧＥＲ-ＶＥＲＬＡＧ *
JPN5013003118; ＧＯＬＥＴＺ　Ｓ: 'ＴＨＯＭＳＥＮ-ＦＲＩＥＤＥＮＲＥＩＣＨ　ＡＮＴＩＧＥＮ：ＴＨＥ　ＨＩＤＤＥＮ　ＴＵＭＯＲ　ＡＮＴＩＧＥＮ' ＡＤＶＡＮＣＥＳ　ＩＮ　ＥＸＰＥＲＩＭＡＮＴＡＬ　ＭＥＤＩＣＩＮＥ　ＡＮＤ　ＢＩＯＬＯＧＹ Ｖ５３５, 20030101, Ｐ１４７-１６２, ＳＰＲＩＮＧＥＲ *
JPN6014050803; Ｃａｎｃｅｒ　Ｒｅｓ．，　Ｖｏｌ．６０　Ｎｏ．１０　ｐ．２５８４-２５８８　（２０００） *
JPN6014050806; Ｃａｎｃｅｒ，　Ｖｏｌ．８５　Ｎｏ．１０　ｐ．２１５１-２１５９　（１９９９） *
JPN6014050808; Ｇｌｙｃｏｂｉｏｌｏｇｙ，　Ｖｏｌ．１１　Ｎｏ．７　ｐ．５８７-５９２　（２００１） *
JPN6014050811; Ｔｕｍｏｕｒ　Ｂｉｏｌ．，　Ｖｏｌ．２９　Ｎｏ．３　ｐ．１６１-８０　（２００８） *
JPN6014050812; Ｉｍｍｕｎｏｂｉｏｌｏｇｙ，　Ｖｏｌ．２１０，　Ｎｏ．６-８，　ｐ．６１７-６１８［Ａ１６］　（２００５） *
JPN6015034318; Ｉｎｔ　Ｊ　Ｃａｎｃｅｒ Ｖｏｌ．１２３, 2008, ｐ．８９-９９ *
JPN6015034319; ＧＥＮＯＭＩＣＳ Ｖｏｌ．１２, 1992, ｐ．７８８-９４ *
JPN6015034320; Ｐｒｏｃ　Ｎａｔｌ　Ａｃａｄ　Ｓｃｉ　ＵＳＡ Ｖｏｌ．９９，　Ｎｏ．９, 2002, ｐ．６２４６-５１ *
JPN6015034321; Ｐｒｏｃ　Ｎａｔｌ　Ａｃａｄ　Ｓｃｉ　ＵＳＡ Ｖｏｌ．９１, 1994, ｐ．１２９５７-６１ *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018510844A (ja) * 2015-01-24 2018-04-19 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ がんマーカーおよびその使用方法
JP2021104998A (ja) * 2015-01-24 2021-07-26 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ がんマーカーおよびその使用方法
JP7329006B2 (ja) 2015-01-24 2023-08-17 アカデミア シニカ 乳がん幹細胞の腫瘍原性を予測する方法
WO2018092885A1 (ja) * 2016-11-18 2018-05-24 アステラス製薬株式会社 新規な抗ヒトＭＵＣ１抗体Ｆａｂフラグメント
JPWO2018092885A1 (ja) * 2016-11-18 2019-10-17 アステラス製薬株式会社 新規な抗ヒトＭＵＣ１抗体Ｆａｂフラグメント
US11679166B2 (en) 2016-11-18 2023-06-20 Astellas Pharma Inc. Anti-human MUC1 antibody Fab fragment
US11667724B2 (en) 2017-07-07 2023-06-06 Astellas Pharma Inc. Anti-human CEACAM5 antibody Fab fragment
US12202908B2 (en) 2018-05-17 2025-01-21 Astellas Pharma Inc. Complex having anti-human MUC1 antibody Fab fragment, peptide linker and/or ligand
US12065503B2 (en) 2018-10-10 2024-08-20 Astellas Pharma Inc. Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex
JP2024504406A (ja) * 2021-01-25 2024-01-31 ユニオジェン・オサケユフティオ 膀胱がんのバイオマーカーとしてのＦＵＣα（１－２）Ｇａｌ糖鎖構造の使用

Also Published As

Publication number Publication date
AU2011208874A1 (en) 2012-08-02
AU2011208874B2 (en) 2015-06-25
WO2011089004A1 (en) 2011-07-28
CN102753199A (zh) 2012-10-24
EP2525832A1 (en) 2012-11-28
EP2347769A1 (en) 2011-07-27
US20120294859A1 (en) 2012-11-22
JP2016047848A (ja) 2016-04-07
CA2786212A1 (en) 2011-07-28
BR112012018132A2 (pt) 2017-06-20

Similar Documents

Publication Publication Date Title
AU2011208874B2 (en) Cancer stem cell markers and uses thereof
JP6672383B2 (ja) 間葉及び上皮間葉形質転換循環腫瘍細胞のための特異的検出ツール
JP5689133B2 (ja) 結腸直腸癌におけるｐｏｄｘｌタンパク質
JP6875129B2 (ja) 直接的な免疫組織化学アッセイ
CN105102978A (zh) 分离循环肿瘤细胞的方法
JP6795813B2 (ja) がん細胞の検出方法、がん細胞内に物質を導入するための試薬、及びがん治療用組成物
US20200200752A1 (en) Compositions and methods for prostate cancer analysis
JP5847755B2 (ja) 細胞を検出する方法、およびこれに有用な薬剤
RU2641968C2 (ru) Композиции и способы анализа рака предстательной железы
JP2020125352A (ja) 抗−ｃｄ４３抗体およびその癌治療用途
Wagner et al. Two birds with one stone: human SIRPα nanobodies for functional modulation and in vivo imaging of myeloid cells
JP2019528437A (ja) 腫瘍関連マクロファージをターゲティングすることによるガン疾患の処置方法
BR112020023265A2 (pt) uso para prevenir e tratar doenças relacionadas a células supressoras derivadas de mieloide
Lin et al. Co-expression of CD173 (H2) and CD174 (Lewis Y) with CD44 suggests that fucosylated histo-blood group antigens are markers of breast cancer-initiating cells
JP2022520383A (ja) 癌細胞上に存在するケラチン１４（ｋｒｔ１４）の細胞外部分を標的とすることによる癌の治療または予防のための方法
Wang et al. In vitro and in vivo properties of CD133 expressing cells from human lung cancer cell lines
US8119774B2 (en) Cell marker for hepatic and pancreatic stem cells and progenitor cells
US9206258B2 (en) Anti-prostate cancer antibodies and methods of detection and treatment of prostate cancer using the same
Lim et al. A monoclonal antibody recognizing CD98 on human embryonic stem cells shows anti-tumor activity in hepatocellular carcinoma xenografts
EP3458097A1 (en) Targeted delivery of therapeutic agents and imaging reagents to pancreatic cancer cells
KR20260051040A (ko) Ror1에 대한 항체 및 이의 용도
JP2018533586A (ja) がん幹細胞を標的にし、そして侵襲性がんを処置するための抗体
BR112018007334B1 (pt) Anticorpo anti-cd43, conjugado e composição do mesmo para tratamento de câncer
HK1255484A1 (en) Compositions and methods for prostate cancer analysis
HK1255484B (en) Compositions and methods for prostate cancer analysis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131212

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20131212

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150302

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150826

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20151225

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160122

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20160304

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170331

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170705

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20180223